There's no such thing as a retatrutide retail price — the drug isn't approved. What people actually pay depends on how they get it. Four channels exist. Each has its own price and its own hidden costs.
Research peptide prices (2026)
At a 4 mg weekly maintenance dose, the effective monthly cost is roughly $240–$280 depending on vial size purchased. Add BAC water ($10 per 30 mL bottle, lasts months), syringes ($0.20 each × 4 = $0.80/mo), alcohol swabs, and the occasional wasted vial from a mixing error, and you're at $260–$300/mo all-in.
What's not in that number: medical oversight, quality assurance, return if the vial is bad, treatment for severe side effects, and the time you spend on reconstitution and dose calculation. See peptide page for a fuller picture of what research peptides are actually like to use.
Compounded retatrutide pricing
Specialty compounding pharmacies that offer retatrutide formulations typically charge $300–$500/month depending on dose, delivery, and whether physician consultations are bundled. The pricing premium over research peptides reflects pharmacy sterility compliance, USP 797/800 infrastructure, and some level of formulation oversight.
The catch: legal and regulatory certainty is low. Retatrutide was never on the FDA drug shortage list (because it was never approved), so compounders offering it operate under more tenuous legal framing than those that handled semaglutide or tirzepatide during the 2023–2024 shortages. Pricing may shift as enforcement evolves.
FDA-approved GLP-1 alternatives: $179–$499/month
Here's where the cost math gets interesting. Direct-pay telehealth providers have re-priced FDA-approved GLP-1 medications over the past two years:
| Medication | Class | Provider / route | Monthly cash | Phase 3 weight loss |
|---|---|---|---|---|
| Semaglutide | GLP-1 | Telehealth compounded | $179–$299 | 14.9% (STEP-1) |
| Semaglutide | GLP-1 | Wegovy branded | $1,349 | 14.9% |
| Tirzepatide | GLP-1 + GIP | Telehealth compounded | $249–$399 | 22.5% (SURMOUNT-1) |
| Tirzepatide | GLP-1 + GIP | Zepbound branded | $1,060 | 22.5% |
| Retatrutide (research peptide) | GLP-1+GIP+glucagon | Grey market | $260+ | 24.2% (trial) |
| Retatrutide (compounded) | GLP-1+GIP+glucagon | Compounding | $300–$500 | 24.2% (trial) |
Read this table carefully. Tirzepatide at $249/month produces 22.5% Phase 3 weight loss. Retatrutide at $260+/month (research peptides, unsupervised, zero quality control) produces 24.2% Phase 2 weight loss. The price is nearly identical. The product quality, medical oversight, and safety margin are very different.
Full cost comparison: retatrutide vs alternatives
Annualized cost at 4 mg weekly maintenance (or equivalent therapeutic dose):
| Channel | Monthly | Annual | Oversight | Quality |
|---|---|---|---|---|
| Research peptide retatrutide | $260 | $3,120 | None | Variable |
| Compounded retatrutide | $350 | $4,200 | Physician in loop | Moderate |
| Telehealth tirzepatide (compounded) | $249 | $2,988 | Full physician oversight | Pharmaceutical grade |
| Telehealth semaglutide (compounded) | $179 | $2,148 | Full physician oversight | Pharmaceutical grade |
| Branded Zepbound (tirzepatide) | $1,060 | $12,720 | Full oversight | Pharmaceutical grade |
| Branded Wegovy (semaglutide) | $1,349 | $16,188 | Full oversight | Pharmaceutical grade |
Hidden costs people don't calculate
- BAC water, syringes, swabs. ~$10–$20/month in supplies for the research-peptide route.
- Wasted vials. A miscalculated reconstitution or a bad batch is a full vial loss.
- Lost time. 15–30 minutes per weekly injection for reconstitution, dose calculation, and logging. 1–2 hours per month.
- Medical risk. ER visits for severe nausea/dehydration are possible on any GLP-1. Insurance vs cash-pay makes a large difference here.
- No money-back guarantee. Research-peptide vendors don't refund; telehealth providers often do.
Will retatrutide be cheaper than tirzepatide after FDA approval?
Near-term: no. Eli Lilly will launch at premium pricing — probably $1,100–$1,400/month cash for commercial pharmacies. Long-term, compounded retatrutide and telehealth programs will pressure prices down, similar to how tirzepatide cash-pay options evolved from $1,300 to $249 over 2022–2025. In 2028–2030, a $199–$299/month telehealth retatrutide option is plausible. Until then, FDA-approved alternatives remain the best price-to-results option.